Nektar Therapeutics
Nektar Therapeutics is dedicated to creating new medicines that address serious medical needs by leveraging cutting-edge chemistry and biology. They focus on advancing therapies that modulate the immune system to treat autoimmune disorders, chronic inflammatory conditions, and cancer, with a mission to bring hope to patients worldwide.
Industries
Nr. of Employees
large (251-1000)
Patents
Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist
US-12233104-B2
View DetailsMulti-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods
US-12214045-B2
View Details
Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist
US-12233104-B2
View DetailsMulti-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods
US-12214045-B2
View DetailsProducts
IL-2 regulatory T cell stimulator (clinical-stage biologic)
A biologic designed to preferentially stimulate regulatory T cells via IL-2 pathway modulation; progressed into Phase 2 clinical studies for autoimmune indications.
IL-15 receptor agonist biologic (clinical-stage)
An IL-15 pathway agonist developed for immuno-oncology and hematologic malignancies; studied in combination with cell therapies and immune checkpoint inhibitors across multiple clinical trials.
PEG-modified hematopoietic colony-stimulating factor (preclinical)
A polyethylene glycol–modified colony-stimulating factor protein intended to alter PK/PD properties for therapeutic applications; currently in preclinical development.
Bivalent agonistic antibody targeting immune receptor (preclinical)
Engineered bivalent antibody agonist directed at an immune regulatory receptor for potential use in immunomodulatory indications; currently at preclinical stage.
Out-licensed technologies used in marketed biologics
Polymer-conjugation and related modification technologies licensed to third parties and applied in marketed therapeutic products.
IL-2 regulatory T cell stimulator (clinical-stage biologic)
A biologic designed to preferentially stimulate regulatory T cells via IL-2 pathway modulation; progressed into Phase 2 clinical studies for autoimmune indications.
IL-15 receptor agonist biologic (clinical-stage)
An IL-15 pathway agonist developed for immuno-oncology and hematologic malignancies; studied in combination with cell therapies and immune checkpoint inhibitors across multiple clinical trials.
PEG-modified hematopoietic colony-stimulating factor (preclinical)
A polyethylene glycol–modified colony-stimulating factor protein intended to alter PK/PD properties for therapeutic applications; currently in preclinical development.
Bivalent agonistic antibody targeting immune receptor (preclinical)
Engineered bivalent antibody agonist directed at an immune regulatory receptor for potential use in immunomodulatory indications; currently at preclinical stage.
Out-licensed technologies used in marketed biologics
Polymer-conjugation and related modification technologies licensed to third parties and applied in marketed therapeutic products.
Services
Collaborative discovery, licensing of molecules and technologies, and co-development arrangements with pharmaceutical and biotech partners.
Access to a research approach combining immunology target selection and polymer-chemistry design to create selective immunomodulatory therapeutics.
Cooperative clinical programs including investigator-sponsored trials and multi-site studies across Phase 1–3.
Collaborative discovery, licensing of molecules and technologies, and co-development arrangements with pharmaceutical and biotech partners.
Access to a research approach combining immunology target selection and polymer-chemistry design to create selective immunomodulatory therapeutics.
Cooperative clinical programs including investigator-sponsored trials and multi-site studies across Phase 1–3.
Expertise Areas
- Immunomodulating therapeutic development
- Autoimmune and inflammatory disease therapeutics
- Oncology immunotherapy and combination regimens
- Polymer-based biologic modification (PEGylation)
Key Technologies
- Polymer chemistry for biologics
- Polyethylene glycol (PEG) modification
- Cytokine-pathway modulation (e.g., IL-2, IL-15)
- Antibody engineering (bivalent agonists)
News & Updates
Nektar will announce top-line data from their Phase 2b study of Rezpegaldesleukin in Atopic Dermatitis during a virtual event on June 24, 2025.
Nektar will present their first quarter 2025 financial results during a virtual webcast on May 8.
Nektar will participate in a virtual conference on March 27, 2024.
9 Million patients benefit from our medicines
12 Approved products around the world
6 R&D Pipeline Programs
Nektar will announce top-line data from their Phase 2b study of Rezpegaldesleukin in Atopic Dermatitis during a virtual event on June 24, 2025.
Nektar will present their first quarter 2025 financial results during a virtual webcast on May 8.
Nektar will participate in a virtual conference on March 27, 2024.